Drug intelligence / Profile preview

TI-0072

Development stage: Preclinical
Lead developer: Therorna
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

TI-0072 is a circular RNA (circRNA) therapeutic candidate being developed by Yuanyin (Beijing) Biotechnology (Therorna) for the treatment of metabolic disorders, including obesity, diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Utilizing Therorna's proprietary circRNA platform, TI-0072 is designed to leverage the enhanced stability and protein-coding potential of circular RNA compared to linear mRNA. The drug is currently in the discovery stage of development.

Beyond the preview

Go deeper on TI-0072.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TI-0072.